The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated safety advice to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on a similar product, dutasteride.<\/p>\n
Following an\u00a0additional\u00a0detailed review of the evidence, including the outcome of a European regulatory review, the MHRA has published a new\u00a0Drug Safety Update<\/a>\u00a0and is updating product information for medicines\u00a0containing\u00a0finasteride and dutasteride to\u00a0provide\u00a0clearer guidance for healthcare professionals and patients.\u00a0<\/p>\n Finasteride is used to treat male pattern hair loss at a dose of\u00a01mg, and benign prostatic hyperplasia at a dose of\u00a05mg.\u00a0Dutasteride\u00a0(0.5mg)\u00a0is used to treat benign prostatic hyperplasia.\u00a0<\/p>\n The updates include:\u00a0<\/p>\n strengthened warnings in the product information for finasteride 1mg for androgenetic alopecia to clarify that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported with and without mood alterations\u00a0<\/p>\n a precautionary warning added to the product information for dutasteride to note that mood alterations have been reported with\u00a0a\u00a0medicine in the same\u00a0class, finasteride\u00a0<\/p>\n Existing UK patient alert cards for finasteride, introduced in 2024, remain in place. These cards highlight the risks of sexual dysfunction, depression and suicidal thoughts and advise patients on what action to take if side effects occur.\u00a0<\/p>\n Dr\u00a0Alison Cave, MHRA Chief Safety Officer, said:\u00a0<\/p>\n \u201cThe MHRA has taken significant action to raise awareness of the risks of sexual dysfunction,\u00a0depression and suicidal thoughts associated with finasteride, including issuing a Drug Safety Update and introducing patient alert cards in 2024.\u00a0<\/p>\n \u201cFollowing an\u00a0additional\u00a0detailed review of the evidence, we have now strengthened product information for both finasteride\u00a01mg\u00a0and dutasteride to\u00a0provide\u00a0clearer guidance on these potential risks and to support informed discussions between healthcare professionals and patients.\u00a0<\/p>\n \u201cPatient safety is our top priority. We expect prescribers to\u00a0discuss\u00a0the relevant safety information\u00a0with\u00a0patients\u00a0so\u00a0they can make informed decisions about their treatment, and we continue to encourage patients and healthcare professionals to report suspected side effects through the Yellow Card scheme.\u201d\u00a0<\/p>\n Patients taking finasteride who experience depression or suicidal thoughts should stop treatment and seek medical advice. Any concerns about sexual side effects should be discussed with a healthcare professional.\u00a0<\/p>\n Suspected adverse reactions can be reported to the MHRA through the\u00a0Yellow Card scheme.<\/a>\u00a0<\/p>\n Notes for editors\u00a0<\/p>\n